Top Page
VentriPoint Diagnostics
(VPT)
VentriPoint Diagnostics (VPT) vs. S&P 500 (SPY)
VentriPoint Diagnostics Business Overview & Revenue Model
VentriPoint Diagnostics Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 136.57K | 49.18K | 68.17K | 0.00 | 36.02K | 81.02K | Gross Profit |
| 103.72K | 42.43K | 57.81K | -48.81K | 26.27K | 37.17K | EBIT |
| -4.99M | -4.93M | -4.91M | -3.72M | -1.89M | -3.28M | EBITDA |
| -4.86M | -4.74M | -4.79M | -3.70M | -1.58M | -3.05M | Net Income Common Stockholders |
| -5.10M | -4.87M | -4.87M | -3.88M | -1.85M | -3.32M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 66.57K | 1.29M | 5.19M | 9.27M | 526.03K | 13.76K | Total Assets |
| 466.49K | 1.88M | 5.98M | 9.54M | 801.57K | 314.28K | Total Debt |
| 0.00 | 412.44K | 459.08K | 159.97K | 1.37M | 1.13M | Net Debt |
| -66.57K | -881.91K | -4.73M | -9.11M | 843.84K | 1.11M | Total Liabilities |
| 1.44M | 1.69M | 1.42M | 1.21M | 3.15M | 2.78M | Stockholders Equity |
| -973.26K | 189.71K | 4.55M | 8.33M | -2.35M | -2.47M |
| Cash Flow | Free Cash Flow | ||||
| -3.66M | -3.80M | -4.14M | -3.15M | -1.10M | -2.40M | Operating Cash Flow |
| -3.66M | -3.80M | -4.14M | -3.15M | -1.10M | -2.38M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | -4.26K | -3.76K | -17.10K | Financing Cash Flow |
| 1.46M | -102.36K | 87.65K | 11.89M | 1.62M | 2.34M |
VentriPoint Diagnostics Technical Analysis
VentriPoint Diagnostics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | C$423.68M | ― | -3.15% | 4.04% | -15.41% | -69.47% | |
51 Neutral | $5.20B | 3.18 | -40.80% | 2.96% | 17.66% | 1.94% | |
44 Neutral | C$22.83M | ― | 207.08% | ― | 280.56% | -7.28% | |
44 Neutral | C$3.89M | ― | -160.58% | ― | 44.96% | -827.30% | |
36 Underperform | C$67.34M | ― | 248.46% | ― | ― | 32.71% |
VentriPoint Diagnostics Corporate Events
Ventripoint Diagnostics has strengthened its sales strategy by appointing Karl Pringle to its Business Advisory Board, aiming to drive global growth of its VMS+ technology by 2025. With Pringle’s extensive experience in healthcare technology and proven track record in driving sales and transformation, the company is poised to expand its market presence and accelerate adoption of its innovative cardiac diagnostic solutions.
Ventripoint Diagnostics Ltd. has announced significant advancements in its cardiac diagnostic technology, particularly with the development of VMS+3.2 and VMS+4.0, which have received CE mark and Health Canada Medical Device License. The company is awaiting FDA clearance for VMS+4.0 and is focusing on further refining the technology, expanding its cardiac indications, and enhancing clinical integration through partnerships and improved training resources. This strategic focus aims to ensure better user experiences and align R&D efforts with market needs.
Ventripoint Diagnostics has updated its submission of the VMS+ 4.0 software to the U.S. FDA, addressing cybersecurity and AI concerns. This upgrade aims to advance clinical workflows with AI-assisted image analysis and simplified sensor pairing. With prior regulatory clearances globally, Ventripoint anticipates U.S. market entry post-FDA approval, potentially strengthening its position in non-invasive cardiac imaging.
VentriPoint Diagnostics Ltd. has announced the successful closing of the second tranche of its non-brokered private placement of unsecured convertible debentures, raising an additional $169,000, bringing the total to $510,000. This financial maneuver is intended to strengthen the company’s capital structure, potentially enhancing its market positioning and providing more opportunities for stakeholders as it continues to develop its cardiac imaging technologies.
Ventripoint Diagnostics Ltd. announced its plan to satisfy debenture interest payments by issuing common shares, pending approval from the TSX Venture Exchange. The issuance of shares will not result in a control person for the corporation, and the shares will be subject to a hold period. This strategic decision aims to manage financial obligations while maintaining operational control, reflecting Ventripoint’s careful financial management and potential impacts on its market position.
Ventripoint Diagnostics Ltd. has announced an extension of its non-brokered private placement of convertible debentures, aiming to raise funds for operational costs and growth. The debentures offer a conversion option into common shares and bear an interest rate of 10% annually. This initiative is part of Ventripoint’s strategy to bolster its sales, marketing, and overall business operations.
Ventripoint Diagnostics and ASCEND Cardiovascular have signed a term sheet for a non-exclusive license to integrate Ventripoint’s VMS+ technology into ASCEND’s Gen3Echo platform, aiming to enhance cardiovascular diagnostics. This collaboration promises to improve diagnostic accuracy and streamline workflows for echocardiographers by combining cutting-edge AI and machine learning technologies.
Ventripoint Diagnostics has announced its plan to issue common shares to satisfy interest payments on its convertible debentures, pending approval from the TSXV. Additionally, the company has revised the terms of its convertible debenture offering, adjusting conversion rates over the term’s duration.
Ventripoint Diagnostics has successfully closed debt settlement agreements by issuing 128,900 common shares to settle $19,335 of debt owed to a former director and their holding company. This strategic move allows Ventripoint to conserve cash for future business development. The shares issued as part of this transaction are subject to approval by the TSX Venture Exchange.
Ventripoint Diagnostics is launching a new sales program to boost its presence in the U.S. market by promoting its AI-powered echocardiography solutions. This initiative aims to enhance cardiovascular diagnostics by offering healthcare providers advanced tools and flexible pricing to improve patient care and reduce costs.
Ventripoint Diagnostics Ltd. has announced a revised non-brokered private placement offering of unsecured convertible debentures worth up to CDN$1,000,000. The debentures, convertible at various price points over the years, aim to attract investors with a 10% annual interest rate and potential automatic conversion into common shares under specific conditions.